In addition, KEGG and GO term analyses of immunotherapy-responsive and non-responsive breast cancer patients revealed that innate immunity-related pathways, including cytokine, chemokine, IL-17, and JAK-STAT signaling pathways, were downregulated in non-responsive patients (Fig. 2f, Supplementary Fig. S2c). This evidence concerns the gene IL17A and breast cancer.